{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-23-000003","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.132234+00:00","generated_at":"2026-06-20T18:23:57.124721+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%","bullets":["Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.","Cash and investments ~$55.0M at Dec 31, down from $59.4M at Sep 30; includes $5.3M capex for new Dayton, OH facility.","115 direct sales reps (flat YoY); 332 Core Accounts (+1% sequential); 968 Active Accounts (+2% sequential).","Surpassed 75,000 Avance Nerve Graft implants since launch; BLA submission planned for H2 2023.","Reaffirms FY22 gross margin above 80%; full FY23 outlook to be provided on March 14, 2023 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-23-000003","json":"https://secwatch.observer/filing/0000805928-23-000003.json","markdown":"https://secwatch.observer/filing/0000805928-23-000003.md","text":"https://secwatch.observer/filing/0000805928-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/0000805928-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/axgn-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:23:57.124721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28937b5a446c1bd2172e11f67b076bdce5e972f7","claim":"Axogen, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202.","evidence_excerpt":"Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/0000805928-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year 2022"},{"label":"Revenue","value":"approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}